The global diaphragm pacing therapy system market is expected to witness growth from 2020 to 2027, majorly owing to rising IMV (Invasive Mechanical Ventilation) complications leading to lung injury, muscle atrophy, and infection. Furthermore, the rising prevalence of spinal cord injuries (SCI) and amyotrophic lateral sclerosis (ALS) are anticipated to fuel adoption. According to the National Spinal Cord Injury Statistical Center, in 2018, 17,730 new spinal cord injury cases are reported yearly in the U.S that account for 54 injuries every million population. Furthermore, favorable advantages of diaphragm pacing therapy system (DPTS) such as reduction of the dependency on mechanical ventilators and improvement of speech and breathing in patients has fostered the market growth.
The ongoing global COVID-19 pandemic resulted in heightened usage of mechanical ventilators which is expected to fuel the DPTS market. This can be attributed to the upsurge demand for ventilation requirements needed during respiratory care in COVID positive patients. Moreover, favorable regulatory policies are further increasing the adoption of this therapy. For e.g. in April 2020, Lungpacer Medical received the U.S. FDA EUA (emergency use authorization) approval for the diaphragm pacing therapy system to assist the weaning COVID patients. These systems can be used as an alternative to the mechanical ventilator for patients with residual function in the lungs, diaphragm, and phrenic nerves.
On the basis of product, the diaphragm pacing therapy system market is segmented into an external diaphragm pacemaker, diaphragm pacemaker. The external diaphragm pacemaker is gaining popularity as it is used in the treatment of congenital central hypoventilation syndrome and cervical spinal cord injury. Furthermore, the diaphragm pacemaker reduces the concern about power outages, and the requirement for an external power source thus increasing the market growth for the segment. Other benefits such as a decline in respiratory infections coupled with increasing mobility in patients have augmented the segment market growth.
On the basis of application, the DPTS market is segmented into spinal cord injury (SCI), amyotrophic lateral sclerosis (ALS) & others. The SCI segment is anticipated to gain popularity due to the increasing number & prevalence SCI cases annually. For instance, according to the data published by the National Spinal Cord Injury Statistical Center, approximately 288,000 patients were living with spinal cord injuries in the U.S in 2018. Furthermore, increasing vehicular crashes, accidents, falls, sports/recreation activities, and other acts of violence have upsurge the SCI patient count and subsequently the demand for diaphragm pacing therapy systems. There is an increased DPTS need for the treatment of ALS patients. This is because ALS involves breathing muscles and if not treated may result in pulmonary problems and respiratory failure. Thus, diaphragm pacing therapy plays a vital role in ALS patient treatment. Furthermore, according to the ALS Association report, nearly 5,000 U.S. citizens are diagnosed with ALS every year. This has fueled the demand for the DPTS market in the segment.
On the basis of region, the market is segmented into five regions. The diaphragm pacing therapy systems market is dominant in North America followed by the European countries due to the high disposable income, and rising healthcare expenditure. Moreover, the presence of major service providers with improved healthcare solutions has fueled the DPTS market. The Asia Pacific region is expected to grow at a lucrative rate during the forecast period. The growth can be attributed to the R&D investments to produce technologically advanced healthcare infrastructure. Furthermore, favorable government initiatives coupled with increasing per capita income is boosting the market growth.
The major market players include Avery Biomedical Devices, Lungpacer Medical, Inc, Synapse Biomedical, and Atrotech. These companies are involved in strategic collaborations, new product launches & regional expansions. For instance, in 2016, the Lungpacer Diaphragm Pacing System received the Expedited Access Pathway (EPA) Designation by the U.S. FDA, which helped in strengthening its market position in the U.S.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."